Denali Therapeutics Inc. $DNLI Stock Acquired by Alps Advisors Inc.

Key Points

• Alps Advisors increased its Denali Therapeutics stake by 32% in the third quarter, adding 51,394 shares to reach 211,772 shares valued at about $4.38 million.
• Denali reported quarterly EPS of $0.37, beating expectations for a $0.27 loss, and revenue of $17.78 million versus a $12.67 million consensus estimate.
• Analysts’ consensus rating is Moderate Buy, with an average price target of $36.15; institutional investors collectively own 92.92% of the stock.

Alps Advisors Inc. lifted its stake in Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) by 32.0% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 211,772 shares of the company's stock after purchasing an additional 51,394 shares during the period. Alps Advisors Inc. owned 0.13% of Denali Therapeutics worth $4,377,000 at the end of the most recent quarter.

Other institutional investors have also recently bought and sold shares of the company. BlackRock Inc. acquired a new position in shares of Denali Therapeutics during the second quarter valued at $360,759,000. Dimensional Fund Advisors LP boosted its stake in shares of Denali Therapeutics by 13.4% in the 1st quarter. Dimensional Fund Advisors LP now owns 2,692,175 shares of the company's stock valued at $51,687,000 after purchasing an additional 317,872 shares during the last quarter. ADAR1 Capital Management LLC boosted its stake in shares of Denali Therapeutics by 3,490.9% in the 1st quarter. ADAR1 Capital Management LLC now owns 1,871,455 shares of the company's stock valued at $35,932,000 after purchasing an additional 1,819,339 shares during the last quarter. Defilade Capital Management L.P. grew its position in shares of Denali Therapeutics by 107.1% during the 1st quarter. Defilade Capital Management L.P. now owns 1,359,969 shares of the company's stock worth $26,111,000 after buying an additional 703,256 shares during the period. Finally, Bank of America Corp DE bought a new stake in shares of Denali Therapeutics during the second quarter worth approximately $31,660,000. Institutional investors own 92.92% of the company's stock.

Denali Therapeutics News Summary

Here are the key news stories impacting Denali Therapeutics this week:

• Positive Sentiment: Denali’s third-quarter results beat expectations: EPS was $0.37 versus the consensus estimate of a $0.27 loss, and revenue was $17.78 million versus a $12.67 million estimate. Denali Therapeutics earnings beat and valuation article
• Positive Sentiment: Commercial momentum and potential catalysts may be lifting sentiment: a report cited nearly fivefold growth in Avlayah sales, broader reimbursement coverage, and multiple upcoming pipeline catalysts. Shares were reported up 7.8% after the earnings release. Zacks report on Denali post-earnings performance
• Positive Sentiment: HC Wainwright initiated coverage with a “Strong Buy” rating, providing a new bullish analyst view. HC Wainwright stock recommendations
• Neutral Sentiment: HC Wainwright’s forecasts show losses continuing in coming years, though its estimates narrow to a $0.14-per-share loss by 2030. The longer-term outlook is therefore still dependent on commercial growth and pipeline progress.
• Neutral Sentiment: A separate report put Denali’s valuation back in focus after the earnings-driven move, suggesting investors may weigh the improved results against the stock’s valuation. Denali earnings and valuation article

Denali Therapeutics Price Performance

Denali Therapeutics stock opened at $20.07 on Monday. The firm has a market capitalization of $3.22 billion, a price-to-earnings ratio of -11.60 and a beta of 1.08. The company's 50 day simple moving average is $20.16 and its 200 day simple moving average is $21.27. The company has a debt-to-equity ratio of 0.01, a current ratio of 6.21 and a quick ratio of 5.94. Denali Therapeutics Inc. has a fifty-two week low of $13.75 and a fifty-two week high of $27.30.

Denali Therapeutics (NASDAQ:DNLI - Get Free Report) last issued its earnings results on Tuesday, November 3rd. The company reported $0.37 EPS for the quarter, beating the consensus estimate of ($0.27) by $0.64. The firm had revenue of $17.78 million during the quarter, compared to the consensus estimate of $12.67 million. During the same period in the previous year, the company posted ($0.74) EPS. As a group, sell-side analysts anticipate that Denali Therapeutics Inc. will post -1.94 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on DNLI shares. Deutsche Bank Aktiengesellschaft increased their price objective on shares of Denali Therapeutics from $31.00 to $35.00 and gave the company a "buy" rating in a report on Thursday, July 16th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Denali Therapeutics in a report on Thursday, October 15th. UBS Group upped their target price on shares of Denali Therapeutics from $25.00 to $34.00 and gave the company a "buy" rating in a research report on Friday, August 7th. B. Riley Financial increased their price target on Denali Therapeutics from $30.00 to $35.00 and gave the company a "buy" rating in a research note on Tuesday, August 25th. Finally, HC Wainwright started coverage on Denali Therapeutics in a research note on Wednesday, November 4th. They issued a "strong-buy" rating on the stock. One research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $36.15.

Insider Activity

In related news, insider Alexander O. Schuth sold 2,857 shares of the company's stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $25.07, for a total value of $71,624.99. Following the completion of the sale, the insider owned 281,763 shares in the company, valued at $7,063,798.41. This represents a 1.00% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 9.70% of the stock is owned by company insiders.

About Denali Therapeutics

Denali Therapeutics is a biotechnology company focused on developing medicines for neurodegenerative diseases and other disorders involving the nervous system. Founded in 2015, the company is headquartered in South San Francisco, California.

Its research and development programs target conditions including Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis and lysosomal storage disorders. Denali's portfolio includes investigational drug candidates that aim to address underlying disease processes, as well as its TransportVehicle platform, designed to help therapeutic molecules cross the blood-brain barrier.

Denali was co-founded by Ryan Watts, who serves as the company's chief executive officer.

Want to see what other hedge funds are holding DNLI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.